Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.
Journal: Nature communications
Published: November 05, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Journal: Nature communications
Published: July 12, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Journal: Gynecologic oncology reports
Published: May 19, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Journal: JCO precision oncology
Published: April 10, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Journal: Gynecologic oncology
Published: February 22, 2025
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
Journal: Gynecologic oncology
Published: March 30, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.
Journal: Gynecologic oncology reports
Published: November 16, 2023
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.
Journal: Journal of the National Cancer Institute
Published: January 09, 2023
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 29, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Journal: JAMA oncology
Published: July 28, 2022
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Journal: The oncologist
Published: May 12, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Journal: International journal of clinical oncology
Published: February 17, 2022
Last Updated: 09/26/2026